Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1988 4
1991 1
1992 2
1993 1
1995 3
1996 4
1997 4
1998 2
1999 3
2000 2
2001 1
2002 4
2003 4
2004 4
2006 1
2007 1
2008 5
2009 3
2010 4
2011 3
2013 3
2014 1
2015 2
2016 6
2017 6
2018 3
2019 2
2020 6
2021 6
2022 1
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

86 results
Results by year
Filters applied: . Clear all
Page 1
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group. Balar AV, et al. Among authors: dawson na. Lancet. 2017 Jan 7;389(10064):67-76. doi: 10.1016/S0140-6736(16)32455-2. Epub 2016 Dec 8. Lancet. 2017. PMID: 27939400 Free PMC article. Clinical Trial.
Intermittent versus continuous androgen deprivation in prostate cancer.
Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr. Hussain M, et al. Among authors: dawson na. N Engl J Med. 2013 Apr 4;368(14):1314-25. doi: 10.1056/NEJMoa1212299. N Engl J Med. 2013. PMID: 23550669 Free PMC article. Clinical Trial.
Berger TG, Dawson NA. Berger TG, et al. Among authors: dawson na. J Am Acad Dermatol. 1988 Feb;18(2 Pt 2):407-12. doi: 10.1016/s0190-9622(88)70058-4. J Am Acad Dermatol. 1988. PMID: 3278019 Review.
Update on hormone-refractory prostate cancer.
Kasamon KM, Dawson NA. Kasamon KM, et al. Among authors: dawson na. Curr Opin Urol. 2004 May;14(3):185-93. doi: 10.1097/00042307-200405000-00008. Curr Opin Urol. 2004. PMID: 15069310 Review.
Suppression of Human Dendritic Cells by Regulatory T Cells.
Huang Q, Lam AJ, Boardman DA, Dawson NAJ, Levings MK. Huang Q, et al. Among authors: dawson naj. Bio Protoc. 2021 Nov 5;11(21):e4217. doi: 10.21769/BioProtoc.4217. eCollection 2021 Nov 5. Bio Protoc. 2021. PMID: 34859131 Free PMC article.
Suramin-induced skin reactions.
O'Donnell BP, Dawson NA, Weiss RB, Myers CE, James WD. O'Donnell BP, et al. Among authors: dawson na. Arch Dermatol. 1992 Jan;128(1):75-9. Arch Dermatol. 1992. PMID: 1531404
86 results